Novel strategies for the prevention and treatment of Candida infections: the potential of immunotherapy
Frank L. Van De Veerdonk,
Mihai G. Netea,
Leo A. Joosten,
Jos W.M. Van Der Meer,
Bart Jan Kullberg,
Frank L. Van De Veerdonk
Department of Medicine, Radboud University Nijmegen Medical Center, Nijmegen Institute for Infection, Inflammation and Immunity (N4i), Nijmegen, The Netherlands
Search for more papers by this authorMihai G. Netea
Department of Medicine, Radboud University Nijmegen Medical Center, Nijmegen Institute for Infection, Inflammation and Immunity (N4i), Nijmegen, The Netherlands
Search for more papers by this authorLeo A. Joosten
Department of Medicine, Radboud University Nijmegen Medical Center, Nijmegen Institute for Infection, Inflammation and Immunity (N4i), Nijmegen, The Netherlands
Search for more papers by this authorJos W.M. Van Der Meer
Department of Medicine, Radboud University Nijmegen Medical Center, Nijmegen Institute for Infection, Inflammation and Immunity (N4i), Nijmegen, The Netherlands
Search for more papers by this authorBart Jan Kullberg
Department of Medicine, Radboud University Nijmegen Medical Center, Nijmegen Institute for Infection, Inflammation and Immunity (N4i), Nijmegen, The Netherlands
Search for more papers by this authorFrank L. Van De Veerdonk,
Mihai G. Netea,
Leo A. Joosten,
Jos W.M. Van Der Meer,
Bart Jan Kullberg,
Frank L. Van De Veerdonk
Department of Medicine, Radboud University Nijmegen Medical Center, Nijmegen Institute for Infection, Inflammation and Immunity (N4i), Nijmegen, The Netherlands
Search for more papers by this authorMihai G. Netea
Department of Medicine, Radboud University Nijmegen Medical Center, Nijmegen Institute for Infection, Inflammation and Immunity (N4i), Nijmegen, The Netherlands
Search for more papers by this authorLeo A. Joosten
Department of Medicine, Radboud University Nijmegen Medical Center, Nijmegen Institute for Infection, Inflammation and Immunity (N4i), Nijmegen, The Netherlands
Search for more papers by this authorJos W.M. Van Der Meer
Department of Medicine, Radboud University Nijmegen Medical Center, Nijmegen Institute for Infection, Inflammation and Immunity (N4i), Nijmegen, The Netherlands
Search for more papers by this authorBart Jan Kullberg
Department of Medicine, Radboud University Nijmegen Medical Center, Nijmegen Institute for Infection, Inflammation and Immunity (N4i), Nijmegen, The Netherlands
Search for more papers by this authorCorrespondence: Frank L. van de Veerdonk, Department of Medicine (463), Nijmegen Institute for Infection, Inflammation and Immunity (N4i), Radboud University Nijmegen Medical Center, PO Box 9101, 6500 HB Nijmegen, The Netherlands. Tel.: +31 24 3616 7204; fax: +31 24 354 1734; e-mail: [email protected]
Editor: Martin Kupiec
Abstract
Infections caused by Candida spp. continue to be a substantial cause of disease burden, especially in immunocompromised patients. New approaches are needed to improve the outcome of patients suffering from Candida infections, because it seems unlikely that the established standard treatment will drastically lower the morbidity of mucocutaneous Candida infections and the high mortality associated with invasive candidiasis. New insights into the mechanisms of the anti-Candida host response have contributed to the design of novel immunotherapeutic approaches that have been proposed as adjuvant therapy in Candida infections. This review presents an overview of novel strategies in the prevention and treatment of Candida infections, with a special focus on adjuvant immunotherapy.
References
- Ahonen P, Myllarniemi S, Sipila I & Perheentupa J (1990) Clinical variation of autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED) in a series of 68 patients. New Engl J Med 322: 1829–1836.
- Babula O, Lazdane G, Kroica J, Ledger WJ & Witkin SS (2003) Relation between recurrent vulvovaginal candidiasis, vaginal concentrations of mannose-binding lectin, and a mannose-binding lectin gene polymorphism in Latvian women. Clin Infect Dis 37: 733–737.
- Babula O, Lazdane G, Kroica J, Linhares IM, Ledger WJ & Witkin SS (2005) Frequency of interleukin-4 (IL-4) −589 gene polymorphism and vaginal concentrations of IL-4, nitric oxide, and mannose-binding lectin in women with recurrent vulvovaginal candidiasis. Clin Infect Dis 40: 1258–1262.
- Bacci A, Montagnoli C, Perruccio K et al. (2002) Dendritic cells pulsed with fungal RNA induce protective immunity to Candida albicans in hematopoetic transplantation. J Immunol 168: 2904–2913.
- Balish E, Wagner RD, Vasquez-Torres A, Pierson C & Warner T (1998) Candidiasis in interferon-gamma knock-out (IFN-gamma−/−) mice. J Infect Dis 178: 478–487.
- Baltch AL, Bopp LH, Smith RP, Ritz WJ, Carlyn CJ & Michelsen PB (2005) Effects of voriconazole, granulocyte-macrophage colony-stimulating factor, and interferon gamma on intracellular fluconazole-resistant Candida glabrata and Candida krusei in human monocyte-derived macrophages. Diagn Micr Infec Dis 52: 299–304.
- Baltch AL, Bopp LH, Smith RP, Ritz WJ & Michelsen PB (2008) Anticandidal effects of voriconazole and caspofungin, singly and in combination, against Candida glabrata, extracellularly and intracellularly in granulocyte-macrophage colony stimulating factor (GM-CSF)-activated human monocytes. J Antimicrob Chemoth 62: 1285–1290.
- Bistoni F, Vecchiarelli A, Cenci E, Puccetti P, Marconi P & Cassone A (1986) Evidence for macrophage-mediated protection against lethal Candida albicans infection. Infect Immun 51: 668–674.
- Black CA, Eyers FM, Russell A, Dunkley ML, Clancy RL & Beagley KW (1998) Acute neutropenia decreases inflammation associated with murine vaginal candidiasis but has no effect on the course of infection. Infect Immun 66: 1273–1275.
- Bodasing N, Seaton RA, Shankland GS & Pithie A (2002) Gamma-interferon treatment for resistant oropharyngeal candidiasis in an HIV-positive patient. J Antimicrob Chemoth 50: 765–766.
- Bozza S, Perruccio K, Montagnoli C et al. (2003) A dendritic cell vaccine against invasive aspergillosis in allogeneic hematopoietic transplantation. Blood 102: 3807–3814.
- Bozza S, Montagnoli C, Gaziano R, Rossi G, Nkwanyuo G, Bellocchio S & Romani L (2004) Dendritic cell-based vaccination against opportunistic fungi. Vaccine 22: 857–864.
- Brach MA, DeVos S, Gruss HJ & Herrmann F (1992) Prolongation of survival of human polymorphonuclear neutrophils by granulocyte-macrophage colony-stimulating factor is caused by inhibition of programmed cell death. Blood 80: 2920–2924.
- Brummer E & Stevens DA (1987) Activation of pulmonary macrophages for fungicidal activity by gamma-interferon or lymphokines. Clin Exp Immunol 70: 520–528.
- Brummer E & Stevens DA (1989) Candidacidal mechanisms of peritoneal macrophages activated with lymphokines or g-interferon. J Med Microbiol 28: 173–181.
- Brummer E, Morrison CJ & Stevens DA (1985) Recombinant and natural gamma-interferon activation of macrophages in vitro: different dosage requirements for induction of killing activity against phagocytizable and nonphagocytizable fungi. Infect Immun 49: 724–730.
- Brummer E, Hanson LH & Stevens DA (1991) Kinetics and requirements for activation of macrophages for fungicidal activity – effect of protein synthesis inhibitors and immunosuppressants on activation and fungicidal mechanism. Cell Immunol 132: 236–245.
- Brunetti L, De Caro F, Boccia G, Cavallo P & Capunzo M (2008) Surveillance of nosocomial infections: a preliminary study on yeast carriage on hands of healthcare workers. J Prev Med Hyg 49: 63–68.
- Cassone A, De Bernardis F & Santoni G (2007) Anticandidal immunity and vaginitis: novel opportunities for immune intervention. Infect Immun 75: 4675–4686.
- Clemons KV & Stevens DA (2000) Treatment of orogastrointestinal candidosis in SCID mice with fluconazole alone or in combination with recombinant granulocyte colony-stimulating factor or interferon-gamma. Med Mycol 38: 213–219.
- Conti HR, Shen F, Nayyar N et al. (2009) Th17 cells and IL-17 receptor signaling are essential for mucosal host defense against oral candidiasis. J Exp Med 206: 299–311.
-
Cutler JE (2001) N-glycosylation of yeast, with emphasis on Candida albicans.
Med Mycol
39S: 75–86.
10.1080/mmy.39.1.75.86 Google Scholar
- Davis SD, Schaller J & Wedgwood RJ (1966) Job's Syndrome. Recurrent, ‘cold’, staphylococcal abscesses. Lancet 1: 1013–1015.
- De Repentigny L, Lewandowski D & Jolicoeur P (2004) Immunopathogenesis of oropharyngeal candidiasis in human immunodeficiency virus infection. Clin Microbiol Rev 17: 729–759.
- Dignani MC, Rex JH, Chan KW et al. (2005) Immunomodulation with interferon-gamma and colony-stimulating factors for refractory fungal infections in patients with leukemia. Cancer 104: 199–204.
- Djeu JY, Blanchard DK, Halkias D & Friedman H (1986) Growth inhibition of Candida albicans by human polymorphonuclear neutrophils: activation by interferon-g and tumor necrosis factor. J Immunol 137: 2980–2984.
- Dongari-Bagtzoglou A & Fidel PL Jr (2005) The host cytokine responses and protective immunity in oropharyngeal candidiasis. J Dent Res 84: 966–977.
- Dongari-Bagtzoglou A & Kashleva H (2003) Candida albicans triggers interleukin-8 secretion by oral epithelial cells. Microb Pathogenesis 34: 169–177.
- Dongari-Bagtzoglou A, Villar CC & Kashleva H (2005) Candida albicans-infected oral epithelial cells augment the anti-fungal activity of human neutrophils in vitro. Med Mycol 43: 545–549.
- Eckert LO (2006) Clinical practice. Acute vulvovaginitis. New Engl J Med 355: 1244–1252.
- Eisenbarth SC, Colegio OR, O'Connor W, Sutterwala FS & Flavell RA (2008) Crucial role for the Nalp3 inflammasome in the immunostimulatory properties of aluminium adjuvants. Nature 453: 1122–1126.
- Ellepola AN & Morrison CJ (2005) Laboratory diagnosis of invasive candidiasis. J Microbiol 43 (spec no.): 65–84.
- Ellis M, Al-Ramadi B, Bernsen R, Kristensen J, Alizadeh H & Hedstrom U (2009) Prospective evaluation of mannan and anti-mannan antibodies for diagnosis of invasive Candida infections in patients with neutropenic fever. J Med Microbiol 58: 606–615.
- Ernst JF & Prill SK (2001) O-glycosylation. Med Mycol 39 (suppl 1): 67–74.
- Eyerich K, Foerster S, Rombold S et al. (2008) Patients with chronic mucocutaneous candidiasis exhibit reduced production of Th17-associated cytokines IL-17 and IL-22. J Invest Dermatol 128: 2640–2645.
- Ferwerda B, Ferwerda G, Plantinga TS et al. (2009) Human dectin-1 deficiency and mucocutaneous fungal infections. New Engl J Med 361: 1760–1767.
- Fidel PL Jr, Barousse M, Espinosa T et al. (2004) An intravaginal live Candida challenge in humans leads to new hypotheses for the immunopathogenesis of vulvovaginal candidiasis. Infect Immun 72: 2939–2946.
- Gadish M, Kletter Y, Flidel O, Nagler A, Slavin S & Fabian I (1991) Effects of recombinant human granulocyte and granulocyte-macrophage colony-stimulating factors on neutrophil function following autologous bone marrow transplantation. Leukocyte Res 15: 1175–1182.
- Gallin JI, Malech HL & Melnick DA and the International Chronic Granulomatous Disease Cooperative Study Group (1991) A controlled trial of interferon gamma to prevent infection in chronic granulomatous disease. New Engl J Med 324: 509–516.
- Gallin JI, Farber JM, Holland SM & Nutman TB (1995) Interferon-gamma in the management of infectious diseases. Ann Intern Med 123: 216–222.
- Garey KW, Rege M, Pai MP, Mingo DE, Suda KJ, Turpin RS & Bearden DT (2006) Time to initiation of fluconazole therapy impacts mortality in patients with candidemia: a multi-institutional study. Clin Infect Dis 43: 25–31.
- Gaviria JM, Van Burik JA, Dale DC, Root RK & Liles WC (1999) Modulation of neutrophil-mediated activity against the pseudohyphal form of Candida albicans by granulocyte colony-stimulating factor (G-CSF) administered in vivo. J Infect Dis 179: 1301–1304.
- Giraldo PC, Babula O, Goncalves AK, Linhares IM, Amaral RL, Ledger WJ & Witkin SS (2007) Mannose-binding lectin gene polymorphism, vulvovaginal candidiasis, and bacterial vaginosis. Obstet Gynecol 109: 1123–1128.
- Glocker EO, Hennigs A, Nabavi M et al. (2009) A homozygous CARD9 mutation in a family with susceptibility to fungal infections. New Engl J Med 361: 1727–1735.
- Gow NAR, Netea MG, Munro CA et al. (2007) Recognition of Candida albicans b-glucan by dectin-1 induces cytokines and has non-redundant effects on the activation of innate immunity. J Infect Dis 196: 1565–1571.
- Graybill JR, Bocanegra R & Luther M (1995) Antifungal combination therapy with granulocyte colony-stimulating factor and fluconazole in experimental disseminated candidiasis. Eur J Clin Microbiol 14: 700–703.
- Grimbacher B, Holland SM, Gallin JI et al. (1999) Hyper-IgE syndrome with recurrent infections – an autosomal dominant multisystem disorder. New Engl J Med 340: 692–702.
- Gudlaugsson O, Gillespie S, Lee K et al. (2003) Attributable mortality of nosocomial candidemia, revisited. Clin Infect Dis 37: 1172–1177.
- Guery BP, Arendrup MC, Auzinger G et al. (2009) Management of invasive candidiasis and candidemia in adult non-neutropenic intensive care unit patients: part II. Treatment. Intens Care Med 35: 206–214.
- Han Y & Cutler JE (1995) Antibody response that protects against disseminated candidiasis. Infect Immun 63: 2714–2719.
- Han Y, Ulrich MA & Cutler JE (1999) Candida albicans mannan extract-protein conjugates induce a protective immune response against experimental candidiasis. J Infect Dis 179: 1477–1484.
- Han Y, Riesselman MH & Cutler JE (2000) Protection against candidiasis by an immunoglobulin G3 (IgG3) monoclonal antibody specific for the same mannotriose as an IgM protective antibody. Infect Immun 68: 1649–1654.
- Herbrecht R, Fohrer C & Nivoix Y (2006) Mycograb for the treatment of invasive candidiasis. Clin Infect Dis 43: 1083; author reply 1083–1084.
- Hernandez-Castro R, Arroyo-Escalante S, Carrillo-Casas EM et al. (2009) Outbreak of Candida parapsilosis in a neonatal intensive care unit: a health care workers source. Eur J Pediatr [Epub ahead of print].
- Hodgetts S, Nooney L, Al-Akeel R, Curry A, Awad S, Matthews R & Burnie J (2008) Efungumab and caspofungin: pre-clinical data supporting synergy. J Antimicrob Chemoth 61: 1132–1139.
- Huang W, Na L, Fidel PL & Schwarzenberger P (2004) Requirement for interleukin-17A for systemic anti-Candida albicans host defense in mice. J Infect Dis 190: 524–631.
- Huang YC, Lin TY, Leu HS, Peng HL, Wu JH & Chang HY (1999) Outbreak of Candida parapsilosis fungemia in neonatal intensive care units: clinical implications and genotyping analysis. Infection 27: 97–102.
- Hubel K, Dale DC & Liles WC (2002) Therapeutic use of cytokines to modulate phagocyte function for the treatment of infectious diseases: current status of granulocyte colony-stimulating factor, granulocyte-macrophage colony-stimulating factor, macrophage colony-stimulating factor, and interferon-gamma. J Infect Dis 185: 1490–1501.
- Ibrahim AS, Spellberg BJ, Avenissian V, Fu Y, Filler SG & Edwards JE Jr (2005) Vaccination with recombinant N-terminal domain of Als1p improves survival during murine disseminated candidiasis by enhancing cell-mediated, not humoral, immunity. Infect Immun 73: 999–1005.
- Ibrahim AS, Spellberg BJ, Avanesian V, Fu Y & Edwards JE Jr (2006) The anti-Candida vaccine based on the recombinant N-terminal domain of Als1p is broadly active against disseminated candidiasis. Infect Immun 74: 3039–3041.
- Iorio E, Torosantucci A, Bromuro C et al. (2008) Candida albicans cell wall comprises a branched beta-d-(1–>6)-glucan with beta-d-(1–>3)-side chains. Carbohyd Res 343: 1050–1061.
- Kaposzta R, Tree P, Marodi L & Gordon S (1998) Characteristics of invasive candidiasis in gamma interferon- and interleukin-4-deficient mice: role of macrophages in host defense against Candida albicans. Infect Immun 66: 1708–1717.
- Kedzierska A, Kochan P, Pietrzyk A & Kedzierska J (2007) Current status of fungal cell wall components in the immunodiagnostics of invasive fungal infections in humans: galactomannan, mannan and (1–>3)-beta-d-glucan antigens. Eur J Clin Microbiol 26: 755–766.
- Kirkpatrick CH (2001) Chronic mucocutaneous candidiasis. Pediatr Infect Dis J 20: 197–206.
- Kullberg BJ, Van ‘t Wout JW, Hoogstraten C & Van Furth R (1993) Recombinant interferon-g enhances resistance to acute disseminated Candida albicans infection in mice. J Infect Dis 168: 436–443.
- Kullberg BJ, Netea MG, Curfs JH, Keuter M, Meis JF & Van Der Meer JW (1998) Recombinant murine granulocyte colony-stimulating factor protects against acute disseminated Candida albicans infection in nonneutropenic mice. J Infect Dis 177: 175–181.
- Kullberg BJ, Netea MG, Vonk AG & Van Der Meer JW (1999) Modulation of neutrophil function in host defense against disseminated Candida albicans infection in mice. FEMS Immunol Med Mic 26: 299–307.
- Kullberg BJ, Oude Lashof AM & Netea MG (2004) Design of efficacy trials of cytokines in combination with antifungal drugs. Clin Infect Dis 39 (suppl 4): S218–S223.
- Lau A, Halliday C, Chen SC, Playford EG, Stanley K & Sorrell TC (2009) Comparison of whole blood, serum and plasma for early detection of Candidemia by multiplex-tandem PCR. J Clin Microbiol 48: 811–816.
- Lavigne LM, Schopf LR, Chung CL, Maylor R & Sypek JP (1998) The role of recombinant IL-12 and IFN-gamma in the pathogenesis of a murine Candida albicans infection. J Immunol 160: 284–292.
- Lechner AJ, Lamprech KE, Potthoff LH, Tredway TL & Matuschak GM (1994) Recombinant GM-CSF reduces lung injury and mortality during neutropenic Candida sepsis. Am J Physiol 266: L561–L568.
- Leibundgut-Landmann S, Osorio F, Brown GD & Reis e Sousa C (2008) Stimulation of dendritic cells via the dectin-1/Syk pathway allows priming of cytotoxic T-cell responses. Blood 112: 4971–4980.
- Leon C, Ruiz-Santana S, Saavedra P et al. (2006) A bedside scoring system (‘Candida score’) for early antifungal treatment in nonneutropenic critically ill patients with Candida colonization. Crit Care Med 34: 730–737.
- Levy DA, Bohbot JM, Catalan F, Normier G, Pinel AM & Dussourd d'Hinterland L (1989) Phase II study of D.651, an oral vaccine designed to prevent recurrences of vulvovaginal candidiasis. Vaccine 7: 337–340.
- Li L & Dongari-Bagtzoglou A (2009) Epithelial GM-CSF induction by Candida glabrata. J Dent Res 88: 746–751.
- Lilic D (2002) New perspectives on the immunology of chronic mucocutaneous candidiasis. Curr Opin Infect Dis 15: 143–147.
- Lin L, Ibrahim AS, Xu X et al. (2009) Th1-Th17 cells mediate protective adaptive immunity against Staphylococcus aureus and Candida albicans infection in mice. PLoS Pathog 5: e1000703.
- Liu F, Liao Q & Liu Z (2006) Mannose-binding lectin and vulvovaginal candidiasis. Int J Gynecol Obstet 92: 43–47.
- Lupetti A, Tavanti A, Davini P et al. (2002) Horizontal transmission of Candida parapsilosis candidemia in a neonatal intensive care unit. J Clin Microbiol 40: 2363–2369.
- Marcil A, Harcus D, Thomas DY & Whiteway M (2002) Candida albicans killing by RAW 264.7 mouse macrophage cells: effects of Candida genotype, infection ratios, and gamma interferon treatment. Infect Immun 70: 6319–6329.
- Marodi L, Schreiber S, Anderson DC, MacDermott RP, Korchak HM & Johnston RB Jr (1993) Enhancement of macrophage Candidacidal activity by interferon-g. Increased phagocytosis, killing, and calcium signal mediated by a decreased number of mannose receptors. J Clin Invest 91: 2596–2601.
- Marquis M, Lewandowski D, Dugas V et al. (2006) CD8+ T cells but not polymorphonuclear leukocytes are required to limit chronic oral carriage of Candida albicans in transgenic mice expressing human immunodeficiency virus type 1. Infect Immun 74: 2382–2391.
- Mata-Haro V, Cekic C, Martin M, Chilton PM, Casella CR & Mitchell TC (2007) The vaccine adjuvant monophosphoryl lipid A as a TRIF-biased agonist of TLR4. Science 316: 1628–1632.
- Matthews RC (1992) The 14th C. L. Oakley Lecture. Candida albicans HSP 90: link between protective and auto immunity. J Med Microbiol 36: 367–370.
- Matthews RC (1994) Pathogenicity determinants of Candida albicans: potential targets for immunotherapy? Microbiology 140: 1505–1511.
- McCluskie MJ & Krieg AM (2006) Enhancement of infectious disease vaccines through TLR9-dependent recognition of CpG DNA. Curr Top Microbiol 311: 155–178.
- Milner JD, Brenchley JM, Laurence A et al. (2008) Impaired T(H)17 cell differentiation in subjects with autosomal dominant hyper-IgE syndrome. Nature 452: 773–776.
- Minegishi Y, Saito M, Tsuchiya S et al. (2007) Dominant-negative mutations in the DNA-binding domain of STAT3 cause hyper-IgE syndrome. Nature 448: 1058–1062.
- Miossec P, Korn T & Kuchroo VK (2009) Interleukin-17 and type 17 helper T cells. New Engl J Med 361: 888–898.
- Mostefaoui Y, Bart C, Frenette M & Rouabhia M (2004) Candida albicans and Streptococcus salivarius modulate IL-6, IL-8, and TNF-alpha expression and secretion by engineered human oral mucosa cells. Cell Microbiol 6: 1085–1096.
- Murciano C, Yanez A, Gil ML & Gozalbo D (2007) Both viable and killed Candida albicans cells induce in vitro production of TNF-alpha and IFN-gamma in murine cells through a TLR2-dependent signalling. Eur Cytokine Netw 18: 38–43.
- Myers TA, Leigh JE, Arribas AR, Hager S, Clark R, Lilly E & Fidel PL Jr (2003) Immunohistochemical evaluation of T cells in oral lesions from human immunodeficiency virus-positive persons with oropharyngeal candidiasis. Infect Immun 71: 956–963.
- Netea MG, De Graaf C, Vonk A, Verschueren I, Van der Meer JWM & Kullberg BJ (2002) The role of Toll-like receptors in the defense against disseminated candidiasis. J Infect Dis 185: 1483–1489.
- Netea MG, Vonk AG, Van Den Hoven M et al. (2003) Differential role of IL-18 and IL-12 in the host defense against disseminated Candida albicans infection. Eur J Immunol 33: 3409–3417.
- Netea MG, Gijzen K, Coolen N et al. (2004) Human dendritic cells are less potent at killing Candida albicans than both monocytes and macrophages. Microbes Infect 6: 985–989.
- Netea MG, Gow NA, Munro CA et al. (2006) Immune sensing of Candida albicans requires cooperative recognition of mannans and glucans by lectin and Toll-like receptors. J Clin Invest 116: 1642–1650.
- Netea MG, Brown GD, Kullberg BJ & Gow NA (2008) An integrated model of the recognition of Candida albicans by the innate immune system. Nat Rev Microbiol 6: 67–78.
- Ohmit SE, Sobel JD, Schuman P, Duerr A, Mayer K, Rompalo A & Klein RS (2003) Longitudinal study of mucosal Candida species colonization and candidiasis among human immunodeficiency virus (HIV)-seropositive and at-risk HIV-seronegative women. J Infect Dis 188: 118–127.
- Ostrosky-Zeichner L, Sable C, Sobel J et al. (2007) Multicenter retrospective development and validation of a clinical prediction rule for nosocomial invasive candidiasis in the intensive care setting. Eur J Clin Microbiol 26: 271–276.
- Pachl J, Svoboda P, Jacobs F et al. (2006) A randomized, blinded, multicenter trial of lipid-associated amphotericin B alone versus in combination with an antibody-based inhibitor of heat shock protein 90 in patients with invasive candidiasis. Clin Infect Dis 42: 1404–1413.
- Pappas PG, Kauffman CA, Andes D et al. (2009) Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis 48: 503–535.
- Pfaller MA & Diekema DJ (2007) Epidemiology of invasive candidiasis: a persistent public health problem. Clin Microbiol Rev 20: 133–163.
- Pietrella D, Rachini A, Torosantucci A et al. (2010) A beta-glucan-conjugate vaccine and anti-beta-glucan antibodies are effective against murine vaginal candidiasis as assessed by a novel in vivo imaging technique. Vaccine 28: 1717–1725.
- Pivarcsi A, Bodai L, Rethi B et al. (2003) Expression and function of Toll-like receptors 2 and 4 in human keratinocytes. Int Immunol 15: 721–730.
- Polonelli L, Lorenzini R, De Bernardis F et al. (1993) Idiotypic vaccination: immunoprotection mediated by anti-idiotypic antibodies with antibiotic activity. Scand J Immunol 37: 105–110.
- Polonelli L, De Bernardis F, Conti S et al. (1994) Idiotypic intravaginal vaccination to protect against Candidal vaginitis by secretory, yeast killer toxin-like anti-idiotypic antibodies. J Immunol 152: 3175–3182.
- Powderly WG, Gallant JE, Ghannoum MA, Mayer KH, Navarro EE & Perfect JR (1999) Oropharyngeal candidiasis in patients with HIV: suggested guidelines for therapy. AIDS Res Hum Retrov 15: 1619–1623.
-
Prella M,
Bille J,
Pugnale M,
Duvoisin B,
Cavassini M,
Calandra T &
Marchetti O (2005) Early diagnosis of invasive candidiasis with mannan antigenemia and antimannan antibodies.
Diagn Micr Infec Dis
51: 95–101.
10.1016/j.diagmicrobio.2004.08.015 Google Scholar
- Redmond HP, Shou J, Gallagher HJ, Kelly CJ & Daly JM (1993) Macrophage-dependent Candidacidal mechanisms in the murine system. Comparison of murine Kupffer cell and peritoneal macrophage Candidacidal mechanisms. J Immunol 150: 3427–3433.
- Richardson MD, Brownlie CE & Shankland GS (1992) Enhanced phagocytosis and intracellular killing of Candida albicans by GM-CSF-activated human neutrophils. J Med Vet Mycol 30: 433–441.
- Richet HM, Andremont A, Tancrede C, Pico JL & Jarvis WR (1991) Risk factors for candidemia in patients with acute lymphocytic leukemia. Rev Infect Dis 13: 211–215.
- Richter SS, Galask RP, Messer SA, Hollis RJ, Diekema DJ & Pfaller MA (2005) Antifungal susceptibilities of Candida species causing vulvovaginitis and epidemiology of recurrent cases. J Clin Microbiol 43: 2155–2162.
- Robinson MJ, Osorio F, Rosas M et al. (2009) Dectin-2 is a Syk-coupled pattern recognition receptor crucial for Th17 responses to fungal infection. J Exp Med 206: 2037–2051.
- Roilides E, Holmes A, Blake C, Pizzo PA & Walsh TJ (1995) Effects of granulocyte colony-stimulating factor and interferon-gamma on antifungal activity of human polymorphonuclear neutrophils against pseudohyphae of different medically important Candida species. J Leukocyte Biol 57: 651–656.
- Rokusz L, Liptay L & Kadar K (2001) Successful treatment of chronic disseminated candidiasis with fluconazole and a granulocyte-macrophage colony-stimulating factor combination. Scand J Infect Dis 33: 784–786.
- Samonis G & Bafaloukos D (1992) Fungal infections in cancer patients: an escalating problem. In Vivo 6: 183–193.
- Sangeorzan JA, Bradley SF, He X, Zarins LT, Ridenour GL, Tiballi RN & Kauffman CA (1994) Epidemiology of oral candidiasis in HIV-infected patients: colonization, infection, treatment, and emergence of fluconazole resistance. Am J Med 97: 339–346.
- Shahar E, Krivoy N & Pollack S (1999) Effective acute desensitization for immediate-type hypersensitivity to human granulocyte-monocyte colony stimulating factor. Ann Allerg Asthma Im 83: 543–546.
- Sobel JD (2007) Vulvovaginal candidosis. Lancet 369: 1961–1971.
- Sobel JD, Faro S, Force RW et al. (1998) Vulvovaginal candidiasis: epidemiologic, diagnostic, and therapeutic considerations. Am J Obstet Gynecol 178: 203–211.
- Sobel JD, Wiesenfeld HC, Martens M et al. (2004) Maintenance fluconazole therapy for recurrent vulvovaginal candidiasis. New Engl J Med 351: 876–883.
- Spellberg BJ, Ibrahim AS, Avenissian V, Filler SG, Myers CL, Fu Y & Edwards JE Jr (2005) The anti-Candida albicans vaccine composed of the recombinant N terminus of Als1p reduces fungal burden and improves survival in both immunocompetent and immunocompromised mice. Infect Immun 73: 6191–6193.
- Spellberg BJ, Ibrahim AS, Avanesian V et al. (2006) Efficacy of the anti-Candida rAls3p-N or rAls1p-N vaccines against disseminated and mucosal candidiasis. J Infect Dis 194: 256–260.
- Tobudic S, Kratzer C, Lassnigg A, Graninger W & Presterl E (2010) In vitro activity of antifungal combinations against Candida albicans biofilms. J Antimicrob Chemoth 65: 271–274.
- Torosantucci A, Bromuro C, Chiani P et al. (2005) A novel glyco-conjugate vaccine against fungal pathogens. J Exp Med 202: 597–606.
- Tramsen L, Beck O, Schuster FR et al. (2007) Generation and characterization of anti-Candida T cells as potential immunotherapy in patients with Candida infection after allogeneic hematopoietic stem-cell transplant. J Infect Dis 196: 485–492.
- Trinchieri G (1995) Interleukin-12: a proinflammatory cytokine with immunoregulatory functions that bridge innate resistance and antigen-specific adaptive immunity. Annu Rev Immunol 13: 251–276.
- Van De Veerdonk FL, Kullberg BJ, Van Der Meer JW, Gow NA & Netea MG (2008) Host–microbe interactions: innate pattern recognition of fungal pathogens. Curr Opin Microbiol 11: 305–312.
- Van De Veerdonk FL, Marijnissen R, Joosten LA, Kullberg BJ, Drenth JP, Netea MG & Van Der Meer JW (2009a) Milder clinical hyperimmunoglobulin E syndrome phenotype is associated with partial interleukin-17 deficiency. Clin Exp Immunol 159: 57–64.
- Van De Veerdonk FL, Marijnissen RJ, Kullberg BJ et al. (2009b) The macrophage mannose receptor induces IL-17 in response to Candida albicans. Cell Host Microbe 5: 329–340.
- Van Eijk M, Van Roomen CP, Renkema GH et al. (2005) Characterization of human phagocyte-derived chitotriosidase, a component of innate immunity. Int Immunol 17: 1505–1512.
- Vazquez JA, Gupta S & Villanueva A (1998) Potential utility of recombinant human GM-CSF as adjunctive treatment of refractory oropharyngeal candidiasis in AIDS patients. Eur J Clin Microbiol 17: 781–783.
- Vazquez JA, Hidalgo JA & De Bono S (2000) Use of sargramostim (rh-GM-CSF) as adjunctive treatment of fluconazole-refractory oropharyngeal candidiasis in patients with AIDS: a pilot study. HIV Clin Trials 1: 23–29.
- Watson MC, Grimshaw JM, Bond CM, Mollison J & Ludbrook A (2002) Oral versus intra-vaginal imidazole and triazole anti-fungal agents for the treatment of uncomplicated vulvovaginal candidiasis (thrush): a systematic review. BJOG-Int J Obstet Gy 109: 85–95.
- Weindl G, Naglik JR, Kaesler S, Biedermann T, Hube B, Korting HC & Schaller M (2007) Human epithelial cells establish direct antifungal defense through TLR4-mediated signaling. J Clin Invest 117: 3664–3672.
- Wells CA, Salvage-Jones JA, Li X et al. (2008) The macrophage-inducible C-type lectin, mincle, is an essential component of the innate immune response to Candida albicans. J Immunol 180: 7404–7413.
- Willment JA, Lin HH, Reid DM et al. (2003) Dectin-1 expression and function are enhanced on alternatively activated and GM-CSF-treated macrophages and are negatively regulated by IL-10, dexamethasone, and lipopolysaccharide. J Immunol 171: 4569–4573.
- Wisplinghoff H, Bischoff T, Tallent SM, Seifert H, Wenzel RP & Edmond MB (2004) Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. Clin Infect Dis 39: 309–317.
- Xin H, Dziadek S, Bundle DR & Cutler JE (2008) Synthetic glycopeptide vaccines combining beta-mannan and peptide epitopes induce protection against candidiasis. P Natl Acad Sci USA 105: 13526–13531.
- Zaoutis TE, Argon J, Chu J, Berlin JA, Walsh TJ & Feudtner C (2005) The epidemiology and attributable outcomes of candidemia in adults and children hospitalized in the United States: a propensity analysis. Clin Infect Dis 41: 1232–1239.
- Zaragoza R, Peman J, Quindos G et al. (2009) Clinical significance of the detection of Candida albicans germ tube-specific antibodies in critically ill patients. Clin Microbiol Infec 15: 592–595.
- Zelante T, De Luca A, Bonifazi P et al. (2007) IL-23 and the Th17 pathway promote inflammation and impair antifungal immune resistance. Eur J Immunol 37: 2695–2706.
- Zhang MX, Bohlman MC, Itatani C, Burton DR, Parren PW, St Jeor SC & Kozel TR (2006) Human recombinant antimannan immunoglobulin G1 antibody confers resistance to hematogenously disseminated candidiasis in mice. Infect Immun 74: 362–369.
